It looks like your browser is outdated. For the best experience, please consider updating to the latest version or switching to another browser (Firefox, Chrome, Safari).
This page is not supported in mobiles. Please view it in the desktop version.
Parenteral cytotoxic agents are among the most highly sophisticated and sensitive drugs to handle and produce. Utilizing RABS (Restricted Access Barrier System) for commercial manufacturing helps BioPharma Solutions to maintain a high level of containment while a product is being manufactured. In addition, this technology helps to maintain the integrity of the molecule, enhance product sterility and ensure the safety of the line operators.
BioPharma Solutions' facility in Halle/Westfalen, Germany, has multiple manufacturing areas with independent air supply and waste disposal systems, including 100% waste collection. In addition, our Halle and Bielefeld facilities are certified by SafeBridge doing both parenteral drug substance synthesis and parenteral drug product manufacturing and testing.
At our recently expanded cytotoxic contract manufacturing facility in Halle/Westfalen, Germany, all your cytotoxic parenteral needs are handled at one manufacturing facility, which allows us to create efficient processing solutions to fit your compound. A dedicated cytotoxic focus helps manage capacity and flexibility, which are critical for maintaining reliable product supply.
For cytotoxic molecules, we offer the following capabilities:
Integrated support services for cytotoxics include:
Proven experience with a variety of molecule classes:
Talk to us at these events